AlloVir Inc (NAS:ALVR)
$ 0.75275 -0.00725 (-0.95%) Market Cap: 86.57 Mil Enterprise Value: -34.78 Mil PE Ratio: 0 PB Ratio: 0.72 GF Score: 30/100

Allovir Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 09:30PM GMT
Release Date Price: $10.82 (-6.16%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome everybody to the 40th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I am one of the senior biotech analysts here at JPMorgan. I'm joined by Priyanka Grover, [Malcolm Kuno] and Caleb Smith from the team. Our next presenting company is AlloVir. And presenting on behalf of the company, we have CEO Diana Brainard.

I want to remind everybody that there is an Ask a Question feature in the portal. If you would like me to ask a question on your behalf, please feel free to put it in the portal, and I will do so.

And with that, Diana, you can take it away.

Diana M. Brainard
AlloVir, Inc. - CEO & Director

Great. Thanks so much, Anupam. Great. Well, I'm delighted to be here as CEO of AlloVir and thrilled to share an update on the incredible progress we've made over the last year, advancing our pipeline of allogeneic off-the-shelf viral-specific T cells.

So I want to start on Slide 3 by walking through a few key numbers that help summarize who

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot